Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179730 | 0.88 | BDKRB1 (0.74) | BDKRB1LMNA | |
| SCHEMBL4175891 | 0.85 | BDKRB1 (0.64) | BDKRB1 | |
| SCHEMBL4177102 | 0.85 | BDKRB1 (0.79) | BDKRB1 | |
| SCHEMBL5502868 | 0.82 | BDKRB1 (0.73) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL5506530 | 0.79 | BDKRB1 (0.68) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL4174733 | 0.78 | BDKRB1 (0.69) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL4180236 | 0.77 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4173172 | 0.77 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL5507903 | 0.77 | BDKRB1 (0.66) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL5509025 | 0.77 | BDKRB1 (0.76) | BDKRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | claimed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | BDKRB1 1/4885KDM4E 3759/4885ALDH1A1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.